Francesca Palandri/LinkedIn
Aug 17, 2026, 16:22
Francesca Palandri: Why Is Ruxolitinib Response So Heterogeneous in Myelofibrosis?
Francesca Palandri, Hematologist at IRCCS Sant’Orsola Polyclinic – Bologna University Hospital, shared on LinkedIn about a recent article she and Filippo Branzanti co-authored, published in Clinical Lymphoma Myeloma and Leukemia, adding:
”Why is ruxolitinib response so heterogeneous in myelofibrosis?
Our SOHO State of the Art review covers:
- Cytopenic vs. proliferative phenotype
- Dose intensity (the 1 modifiable factor)
- HMR mutations, RAS/CBL, cytogenetics
- Dynamic models RR6, iRR6, STR-PM
Moving from static baseline prognostication to response-driven precision medicine.”
Title: SOHO State of the Art Updates and Next Questions | Predictive Markers for Ruxolitinib in Myelofibrosis
Authors: Francesca Palandri, Filippo Branzanti

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments